NYSE:EW - New York Stock Exchange, Inc. - US28176E1082 - Common Stock - Currency: USD
77.83
-0.21 (-0.27%)
The current stock price of EW is 77.83 USD. In the past month the price increased by 10.24%. In the past year, price decreased by -11.54%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.28 | 234.48B | ||
ISRG | INTUITIVE SURGICAL INC | 72.93 | 199.70B | ||
BSX | BOSTON SCIENTIFIC CORP | 39.46 | 157.58B | ||
SYK | STRYKER CORP | 31.09 | 148.69B | ||
MDT | MEDTRONIC PLC | 16.17 | 110.77B | ||
BDX | BECTON DICKINSON AND CO | 12.54 | 50.73B | ||
IDXX | IDEXX LABORATORIES INC | 45.36 | 41.91B | ||
RMD | RESMED INC | 27.33 | 36.38B | ||
DXCM | DEXCOM INC | 52.93 | 34.25B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.62 | 32.90B | ||
STE | STERIS PLC | 26.82 | 24.61B | ||
PODD | INSULET CORP | 90.71 | 23.04B |
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 15,800 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
EDWARDS LIFESCIENCES CORP
One Edwards Way
Irvine CALIFORNIA 92614 US
CEO: Michael A. Mussallem
Employees: 15800
Phone: 19492502500
The current stock price of EW is 77.83 USD. The price decreased by -0.27% in the last trading session.
The exchange symbol of EDWARDS LIFESCIENCES CORP is EW and it is listed on the New York Stock Exchange, Inc. exchange.
EW stock is listed on the New York Stock Exchange, Inc. exchange.
41 analysts have analysed EW and the average price target is 82 USD. This implies a price increase of 5.35% is expected in the next year compared to the current price of 77.83. Check the EDWARDS LIFESCIENCES CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
EDWARDS LIFESCIENCES CORP (EW) has a market capitalization of 45.76B USD. This makes EW a Large Cap stock.
EDWARDS LIFESCIENCES CORP (EW) currently has 15800 employees.
EDWARDS LIFESCIENCES CORP (EW) has a support level at 76.11 and a resistance level at 78. Check the full technical report for a detailed analysis of EW support and resistance levels.
The Revenue of EDWARDS LIFESCIENCES CORP (EW) is expected to grow by 2.24% in the next year. Check the estimates tab for more information on the EW EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
EW does not pay a dividend.
EDWARDS LIFESCIENCES CORP (EW) will report earnings on 2025-07-22, after the market close.
The PE ratio for EDWARDS LIFESCIENCES CORP (EW) is 29.93. This is based on the reported non-GAAP earnings per share of 2.6 and the current share price of 77.83 USD. Check the full fundamental report for a full analysis of the valuation metrics for EW.
The outstanding short interest for EDWARDS LIFESCIENCES CORP (EW) is 1.42% of its float. Check the ownership tab for more information on the EW short interest.
ChartMill assigns a technical rating of 7 / 10 to EW. When comparing the yearly performance of all stocks, EW is a bad performer in the overall market: 60.56% of all stocks are doing better.
ChartMill assigns a fundamental rating of 7 / 10 to EW. EW has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Over the last trailing twelve months EW reported a non-GAAP Earnings per Share(EPS) of 2.6. The EPS increased by 1.96% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 76.28% | ||
ROA | 31.98% | ||
ROE | 41.75% | ||
Debt/Equity | 0.06 |
ChartMill assigns a Buy % Consensus number of 74% to EW. The Buy consensus is the average rating of analysts ratings from 41 analysts.
For the next year, analysts expect an EPS growth of -2.56% and a revenue growth 2.24% for EW